Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological A...( 94 Percent of Men Maintained Nor...),Health

94 Percent of Men Maintained Normal Testosterone Levels Throughout

Treatment

92 Percent of Men Expressed Satisfaction with NEBIDO

LEXINGTON, Mass., May 20 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that data on NEBIDO(R) (testosterone undecanoate), an investigational, long-acting intramuscular injection for the treatment of hypogonadism, was presented in a late breaker presentation at the 2008 American Urological Association Annual Meeting held in Orlando. The data, which had been previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated with NEBIDO for 24 weeks. This study demonstrated that 94 percent of the men had their testosterone levels restored and maintained to within normal levels; further, 92 percent of these men expressed satisfaction with their NEBIDO treatment. Sixty-two percent of men participating in the Phase III study had previously used other testosterone treatments.

"An estimated four to five million men in the U.S. suffer from a common but treatable condition called hypogonadism, or low testosterone. Men with this condition experience decreased libido, fatigue, depression, and muscle loss," said Abraham Morgentaler, MD, Associate Clinical Professor of Urology at Harvard Medical School. "Low testosterone is associated with other significant health issues including diabetes, obesity, cardiovascular disease, and osteoporosis. Low testosterone is under-recognized and under-treated. Results of a Phase III study on a long-acting testosterone injection called testosterone undecanoate (NEBIDO) revealed that a very high pe
'/>"/>